Dubai \u2013 Astra Industrial Group announced a sharp contraction in its financial performance for the third quarter of 2026, with net profits falling by 29.9 percent compared to the previous quarter. The company recorded earnings of 35.9 million dollars, equivalent to 134.7 million riyals, down from 51.2 million dollars in the second quarter of the same year. This quarterly decline was accompanied by a significant reaction in the stock market, where Astra Industrial shares led the market\u2019s losers, dropping by 10 percent to close at 102.40 riyals.<\/p>\n
On an annual basis, the group\u2019s net profit decreased by 19.5 percent, falling from 44.7 million dollars recorded in the third quarter of 2025. In its statement on the Saudi Exchange, the company attributed this year-over-year drop primarily to a reduction in total gross profit across its pharmaceutical and specialized chemicals sectors. Despite these challenges, the firm noted that selling, distribution, general, and administrative expenses, along with provisions for impairment of financial assets, had decreased, which partially offset the margin pressures.<\/p>\n
Total revenues also faced downward pressure, declining by 19.7 percent in the current quarter to reach 156.3 million dollars, or 586.1 million riyals. This represents a decrease from the 194.7 million dollars generated during the corresponding period last year. The revenue slump reflects broader operational headwinds affecting the group\u2019s core business units, requiring management to adjust strategic outlooks for the remainder of the fiscal year.<\/p>\n
Looking at the cumulative results for the first nine months of 2026, net profits fell by 2.8 percent to stand at 133.3 million dollars, compared to 137.1 million dollars in the same period of 2025. The company explained that this slight erosion in profitability over the nine-month horizon was caused by reduced sales volumes in the iron industries and specialized chemicals sectors. Furthermore, the persistent decline in gross profit margins within the pharmaceutical and specialized chemicals divisions continued to weigh on overall earnings, signaling ongoing structural challenges in these specific market segments.<\/p>\n
This story was produced in the newsroom from the disclosed sources named above.<\/em><\/p>\n